Work

Targeted therapy for fusion-driven high-risk acute leukemia

Year: 2018

Type: article

Abstract: Despite continued progress in drug development for acute leukemias, outcomes for patients with some subtypes have not changed significantly in the last decade. Recurrent chromosomal translocations have long been recognized as driver events in leukemia, and many of these oncogenic fusions portend high-risk disease. Improved understanding of the molecular underpinnings of these fusions, coupled with novel chemistry approaches, now provide new opportunity for therapeutic inroads into the treatment of leukemia driven by these fusions.

Source: Blood

DOI: 10.1182/blood-2018-04-784157

Authors: Yana Pikman, Kimberly Stegmaier

Institutions: Boston Children's Hospital, Dana-Farber Cancer Institute, Broad Institute, Harvard University, Massachusetts Institute of Technology

Language: English

Topic: Acute Myeloid Leukemia Research

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: Gilead Sciences, National Institutes of Health, National Cancer Institute